Related Experiment Video
Updated: Jul 5, 2026
07:01
Electrophoretic Delivery of γ-aminobutyric Acid (GABA) into Epileptic Focus Prevents Seizures in Mice
Published on: May 16, 2019
Galanin and epilepsy.
J T Lerner1, R Sankar, A M Mazarati
1Dept. of Pediatrics, Neurology Division, D. Geffen School of Medicine at the University of California, Los Angeles, BOX 951752, 22-474 MDCC, Los Angeles, California 90095-1752, USA.
Cellular and Molecular Life Sciences : CMLS
|May 27, 2008
Summary
Galanin peptide demonstrates significant anticonvulsant properties, effectively reducing seizure activity in animal models. This peptide shows promise for developing novel galanin-based antiepileptic drugs.
Area of Science:
- Neuroscience
- Pharmacology
Background:
- Galanin's neuroanatomical distribution and physiological roles suggest involvement in seizure regulation.
- Evidence indicates galanin influences the initiation and spread of epileptic activity.
Purpose of the Study:
- To investigate the role of galanin and its receptors in epilepsy.
- To evaluate the potential of galanin-based therapies for epilepsy treatment.
Main Methods:
- Administration of galanin receptor agonists and antagonists in animal models of epilepsy.
- Genetic manipulation (gene deletion and overexpression) of galanin and its receptors in transgenic mice.
- Utilizing virus vector transfection to modulate galanin levels in seizure pathways.
Main Results:
- Galanin receptor agonists attenuated seizure responses in animal models.
- Blocking galanin receptors resulted in proconvulsant effects.
- Genetic deletion of galanin or its type 1 receptor led to spontaneous seizures or increased seizure susceptibility.
- Overexpression of galanin inhibited seizure progression.
- Galanin exerts anticonvulsant effects via both type 1 and type 2 receptors.
Conclusions:
- Galanin possesses significant anticonvulsant properties mediated through its receptors.
- Synthetic galanin receptor agonists show potential for systemic administration and development as novel antiepileptic drugs.
More Related Videos
Related Concept Videos
01:18Antiepileptic Drugs: GABAergic Pathway Potentiators
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
01:24Epilepsy and Seizures: Overview
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
01:20Antiepileptic Drugs: Potassium Channel Activators
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
01:14Antiepileptic Drugs: Glutamate Antagonists
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
01:22Epilepsy ll: Types
Recurrent seizures, stemming from abnormal electrical activity in the brain, are the defining characteristic of epilepsy, a chronic neurological condition. Because seizure features vary greatly, epilepsy is classified using two systems: by seizure type and by epilepsy syndromes. These classifications enable clinicians to describe seizure patterns and select suitable treatment strategies.I. Classification by Seizure Type1. Focal EpilepsyFocal epilepsy begins in one hemisphere of the brain.
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...